New study aims to prevent heart rate spikes during breathing tube insertion

NCT ID NCT07089173

Recruiting now Knowledge-focused Sponsor: Peking University Shenzhen Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests 99 adults having planned surgery to find the right remifentanil dose that keeps heart rate and blood pressure stable when a breathing tube is inserted. Patients receive either lidocaine, sufentanil, or a placebo alongside etomidate to see which combination works best. The goal is to improve safety during anesthesia induction.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: remifentanil, lidocaine, sufentanil, etomidate
What this could lead to: If successful, this could help anesthesiologists choose the safest drug combination to prevent dangerous heart rate spikes during intubation.
What could go wrong: This is a small, early-phase study (99 people) focused on a specific procedure, so results may not apply to all patients or surgeries. Side effects like low oxygen or muscle jerks are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMODYNAMICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMODYNAMICS

Contacts and locations

Locations

Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.